Biological and Pharmaceutical Bulletin · 2005 · 58 citations · 10 references
MedicineNeurosciencePharmacologyBehavioral PharmacologyNeurodegenerationNeuropharmacologyDopaminergic PharmacologyNeurochemical PharmacologyNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyNeuroprotectionNeuroprotective PharmacologyIntraperitoneal AdministrationNeuroprotective PharmacotherapyNeurotrophic Factor SignalingProphylactic UseRodent NeuropharmacologyTyrosine Hydroxylase Regulation
The aim of this study was to determine whether sesamin, a component from Acanthopanax senticosus HARMS (ASH) pharmacologically offers protection against Parkinson's disease (PD) and its related depressive behavior in rats administered rotenone. We also examined how sesamin affected the rotenone-induced loss of tyrosine hydroxylase (TH) or glial cell line-derived neurotrophic factor (GDNF)-positive neurons in the midbrain of rats. Rats were orally administered sesamin (3, 30 mg/kg) once a day for 2 weeks before an intraperitoneal injection of rotenone (2.5 mg/kg). The pole test and catalepsy test were used to evaluate the effects of sesamin administration on bradykinesia and depressive behaviors in the PD model of rats given rotenone for 5 weeks. Those effects were compared with the ASH administrated group (250 mg/kg). Treatment with sesamin for seven weeks resulted in prophylactic effects on rotenone-induced parkinsonian bradykinesia and catalepsy, and the effects were equivalent to ASH effects. Immunohistochemistical analysis using TH or GDNF antibody showed that sesamin provided cytoprotective effects against rotenone-induced loss of DA cells. The results suggest that it may be possible to use the ASH and sesamin for the prevention of nigral degenerative disorders, e.g., PD with depression, caused by exposure to pesticide or environmental neurotoxins in general.
10
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Ranjita Betarbet, Todd Sherer, Gillian M. MacKenzie et al. · Nature Neuroscience · 2000 · 3.7K citations
Functional recovery in parkinsonian monkeys treated with GDNF
Don M. Gash, Zhiming Zhang, Aliza Ovadia et al. · Nature · 1996 · 964 citations
Medicine, Neurology, Neuroscience +14
Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy
DL Choi-Lundberg, Qing Lin, Yung‐Nien Chang et al. · Science · 1997 · 631 citations · Full text
Medicine, Neurobiology, Neuroscience +17
Takahiko Fujikawa, Akihiko Yamaguchi, Isao Morita et al. · Biological and Pharmaceutical Bulletin · 1996 · 137 citations · Full text